[go: up one dir, main page]

PE20090761A1 - Productos extruidos con enmascaramiento del sabor mejorado - Google Patents

Productos extruidos con enmascaramiento del sabor mejorado

Info

Publication number
PE20090761A1
PE20090761A1 PE2008000928A PE2008000928A PE20090761A1 PE 20090761 A1 PE20090761 A1 PE 20090761A1 PE 2008000928 A PE2008000928 A PE 2008000928A PE 2008000928 A PE2008000928 A PE 2008000928A PE 20090761 A1 PE20090761 A1 PE 20090761A1
Authority
PE
Peru
Prior art keywords
extruded products
improved flavor
glycerol
flavor masking
flavor
Prior art date
Application number
PE2008000928A
Other languages
English (en)
Inventor
Venkata-Rangarao Kanikanti
Hans-Juergen Hamann
Peter Kleinebudde
Andrea Michalk
Claudia Reitz
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39790368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090761(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of PE20090761A1 publication Critical patent/PE20090761A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seasonings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Fats And Perfumes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

SE REFIERE A UN PRODUCTO EXTRUDIO QUE CONTIENE UN SOPORTE LIPIDICO SELECCIONADO DE ESTER DE GLICEROL CON ACIDOS GRASOS C12-C24, DIBEHENATO DE GLICEROL, TRIMIRISTATO, TRIPALMITATO, TRIESTERATO DE GLICEROL Y COADYUVANTES O ADITIVOS FARMACEUTICAMENTE ACEPTABLES. DICHO PRODUCTO EXTRUIDO TIENE UN DIAMETRO DE HEBRA DE 0,3mm O INFERIOR Y ES UTIL PARA LA PREPARACION DE MEDICAMENTOS DE SABOR ENMASCARADO O DE SABOR ENCUBIERTO
PE2008000928A 2007-06-08 2008-06-02 Productos extruidos con enmascaramiento del sabor mejorado PE20090761A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007026550A DE102007026550A1 (de) 2007-06-08 2007-06-08 Extrudate mit verbesserter Geschmacksmaskierung

Publications (1)

Publication Number Publication Date
PE20090761A1 true PE20090761A1 (es) 2009-07-23

Family

ID=39790368

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000928A PE20090761A1 (es) 2007-06-08 2008-06-02 Productos extruidos con enmascaramiento del sabor mejorado

Country Status (36)

Country Link
US (1) US20100197571A1 (es)
EP (1) EP2170272B1 (es)
JP (2) JP5775302B2 (es)
KR (2) KR101600800B1 (es)
CN (1) CN101677946A (es)
AR (1) AR066914A1 (es)
AU (1) AU2008258887B2 (es)
BR (1) BRPI0812432B8 (es)
CA (1) CA2689486C (es)
CL (1) CL2008001575A1 (es)
CO (1) CO6260054A2 (es)
CR (1) CR11096A (es)
DE (1) DE102007026550A1 (es)
DK (1) DK2170272T3 (es)
DO (1) DOP2009000255A (es)
EC (1) ECSP099716A (es)
ES (1) ES2625138T3 (es)
GT (1) GT200900287A (es)
HR (1) HRP20170747T1 (es)
HU (1) HUE032719T2 (es)
IL (1) IL201708A0 (es)
MX (1) MX2009011999A (es)
MY (1) MY157780A (es)
NI (1) NI200900198A (es)
NZ (1) NZ581670A (es)
PE (1) PE20090761A1 (es)
PL (1) PL2170272T3 (es)
PT (1) PT2170272T (es)
RU (2) RU2009148576A (es)
SI (1) SI2170272T1 (es)
SV (1) SV2009003403A (es)
TW (1) TWI483738B (es)
UA (1) UA97401C2 (es)
UY (1) UY31117A1 (es)
WO (1) WO2008148484A1 (es)
ZA (1) ZA200908647B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172191A1 (en) * 2008-10-01 2010-04-07 Heinrich-Heine-Universität Düsseldorf Lipid pellets with enhanced taste-masking
JP5860284B2 (ja) * 2008-12-05 2016-02-16 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 針状の活性物質を含む押出物
DE102009012423A1 (de) * 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Zubereitung auf Ölbasis
HU231017B1 (hu) 2012-05-08 2019-11-28 LAVET Gyógyszeripari Kft. Praziquantel tartalmú ízfedett formulációk
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
EP3181317A1 (de) * 2015-12-18 2017-06-21 LANXESS Deutschland GmbH Verfahren zur herstellung von feststoffpartikeln
CN108888598A (zh) * 2018-08-01 2018-11-27 江西成必信生物科技有限公司 口服易吸收的布他磷及其制备方法
CN111529499B (zh) * 2020-06-11 2021-09-17 华中农业大学 一种兽用恩诺沙星风味片剂及其制备方法
CA3191671A1 (en) 2020-09-04 2022-03-10 Elanco Us Inc. Palatable formulations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
JPS61240963A (ja) * 1985-04-18 1986-10-27 ユニチカ株式会社 創傷被覆保護材
IN166416B (es) 1985-09-18 1990-05-05 Pfizer
JP2579610B2 (ja) * 1990-09-28 1997-02-05 鳥取大学長 生体内充填剤
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
AUPM969994A0 (en) * 1994-11-28 1994-12-22 Virbac S.A. Equine anthelmintic formulations
JP3418274B2 (ja) * 1995-06-05 2003-06-16 日本化薬株式会社 口腔内感触の良好な錠剤
EP0882049B1 (de) 1996-02-23 2002-11-20 Bayer Ag Gegebenenfalls substituierte 8-cyan-1-cyclopropyl-7-(2,8-diazabicyclo- 4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre derivate
DE19628776A1 (de) * 1996-07-17 1998-01-22 Bayer Ag Oral applizierbare Granulate von Hexahydropyrazinderivaten
EP0959891A1 (en) * 1996-07-30 1999-12-01 Ashmont Holdings Limited Anthelmintic formulations
FR2753904B1 (fr) 1996-10-01 1998-10-30 Gattefosse Ets Sa Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
CA2227314A1 (en) 1997-01-24 1998-07-24 Hoechst Aktiengesellschaft Preparation of concealed taste preparations of antibacterially active quinolone derivatives
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
CA2338996A1 (en) * 1998-07-31 2000-02-10 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical composition having improved taste
DE19854355A1 (de) 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
US6500463B1 (en) * 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
CA2413702A1 (en) * 2000-06-28 2002-01-03 Teva Pharmaceuticals Industries Ltd. Carvedilol
US20020122824A1 (en) 2001-01-24 2002-09-05 Francisco Cabrera Solid phase dispersion of quinolone-or naphthyridonecarboxylic acids
US20040234580A1 (en) 2001-10-05 2004-11-25 Huber Gordon R. Animal feeds including actives and methods of using the same
US6716448B2 (en) * 2001-10-05 2004-04-06 Rubicon Scientific Llc Domesticated household pet food including maintenance amounts of ivermectin
DE10208344A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
US20030190343A1 (en) 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
US20060147527A1 (en) * 2002-12-13 2006-07-06 Cilag Ag Controlled release preparations comprising tramadol and topiramate
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005065663A1 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone and metformin formulations
JP4210615B2 (ja) * 2004-03-26 2009-01-21 エスエス製薬株式会社 不快な味がマスキングされた製剤
DE102004015981A1 (de) * 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
US8236349B2 (en) * 2004-04-12 2012-08-07 Bend Research Inc. Taste-masked drugs in rupturing multiparticulates
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
JP4731941B2 (ja) * 2005-02-14 2011-07-27 大正薬品工業株式会社 経口製剤用粒子
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins

Also Published As

Publication number Publication date
KR20150110825A (ko) 2015-10-02
ECSP099716A (es) 2009-12-28
UA97401C2 (ru) 2012-02-10
UY31117A1 (es) 2009-01-30
CN101677946A (zh) 2010-03-24
DOP2009000255A (es) 2009-12-15
SI2170272T1 (sl) 2017-06-30
PT2170272T (pt) 2017-05-24
NI200900198A (es) 2011-12-14
US20100197571A1 (en) 2010-08-05
BRPI0812432A2 (pt) 2014-12-02
AU2008258887A1 (en) 2008-12-11
JP2014114310A (ja) 2014-06-26
DK2170272T3 (en) 2017-06-06
ZA200908647B (en) 2011-02-23
CA2689486C (en) 2016-03-22
KR101600800B1 (ko) 2016-03-08
BRPI0812432B8 (pt) 2021-05-25
CR11096A (es) 2010-06-28
KR20100017385A (ko) 2010-02-16
SV2009003403A (es) 2010-05-17
ES2625138T3 (es) 2017-07-18
MX2009011999A (es) 2009-11-19
AU2008258887B2 (en) 2014-06-26
DE102007026550A1 (de) 2008-12-11
JP2010529059A (ja) 2010-08-26
CO6260054A2 (es) 2011-03-22
NZ581670A (en) 2012-07-27
CA2689486A1 (en) 2008-12-11
RU2014124814A (ru) 2015-12-27
MY157780A (en) 2016-07-29
HRP20170747T1 (hr) 2017-07-28
JP5775302B2 (ja) 2015-09-09
BRPI0812432B1 (pt) 2019-04-16
EP2170272A1 (de) 2010-04-07
GT200900287A (es) 2011-11-09
HUE032719T2 (en) 2017-10-30
IL201708A0 (en) 2010-05-31
RU2009148576A (ru) 2011-07-20
CL2008001575A1 (es) 2008-12-19
AR066914A1 (es) 2009-09-23
WO2008148484A1 (de) 2008-12-11
EP2170272B1 (de) 2017-03-29
TWI483738B (zh) 2015-05-11
TW200914051A (en) 2009-04-01
PL2170272T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
PE20090761A1 (es) Productos extruidos con enmascaramiento del sabor mejorado
MX2020008890A (es) Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
ES2620456T3 (es) Derivados polisacáridos de ácido lipoico, su preparación, uso como productos cosméticos para la piel y dispositivos médicosmédicos
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
MX386820B (es) Microcápsulas lipídicas que comprenden de preferencia un retinoide y composición que las contiene, su procedimiento de preparación y su uso en dermatología.
AR095182A1 (es) Composiciones de estatinas y ácidos grasos omega-3
CL2012002013A1 (es) Microorganismos aislado thrastochytrium sp. atcc pta-10212 util en la produccion de acidos grasos omega-3
MX2012006875A (es) Composicion de recubrimiento para productos frescos que comprenden chitosan, agente tensioactivo y polietilenglicol.
BR112012014842A2 (pt) perfumes e encapsulados de perfume
EA201600471A1 (ru) Экстрагированный растительный липид, содержащий длинноцепочечные полиненасыщенные жирные кислоты
BR112014019927A8 (pt) fórmula nutricional, método de preparação da referida fórmula antes da sua ingestão por um indivíduo, uso da referida fórmula, dispositivo para prepará-la e recipiente
WO2008093848A1 (ja) ホスファチジルコリンを含有する炎症マーカー低減組成物
CL2010001587A1 (es) Proceso de preparacion de un concentrado de etil esteres de acidos grasos omega-3 que comprende sobre el 80% en peso de dichos esteres en configuracion cis y sus dobles enlaces separados por una unidad metilenica.
NZ700732A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2011116738A3 (de) Neuartiges trägersystem für den transport von wirkstoffen in die haut
AR070320A1 (es) Metodos para alimentar cerdos y productos que comprenden acidos grasos beneficos
AR060730A1 (es) Formulacion de medicamento liquida
TW200640442A (en) Tablets comprising a biologically active substance and an excipient
BRPI1011630B8 (pt) paracetamol para a administração parenteral
CO2017005911A2 (es) Método para incrementar niveles de ácidos grasos de omega-3 en productos de carne de res por medio de administración de una dieta de pasto y algas
CL2011001539A1 (es) Compuestos derivados de un acido graso poliinsaturado omega 3 u omega 6 y un ester de diol con actividad anti-inflamatoria y antibacteriana; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento del acne o la dermatitis seborreica.
AR019810A1 (es) Mezclas de lipidos y su uso.
SV2011003919A (es) Extrudidos con sustancias activas con forma de agujas
TH101627A (th) สิ่งอัดรีดที่มีการปิดบังรสชาติให้ดีขึ้น
AR116761A2 (es) Lípido que comprende ácidos grasos poliinsaturados de cadena larga

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed